Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYCPF9)

• Drug Name: CB-182804 Drug Info
• Synonyms: Polymyxin B analog (iv antibiotic, multidrug-resistant Gram negative bacterial infection), Cubist/BioSource

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 52918383
  TTD Drug ID: DMYCPF9

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Cell membrane (Bact CM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[3]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[4]
Delamanid	DMXE76K	Multi-drug resistant tuberculosis	MG52.00	Approved	[5]
Diphtheria-tetanus vaccine	DM0FSIM	Clostridium infection	1A04	Approved	[6]
D2A21	DMYJ2QB	Burn and burn infection	ND90-NE2Z	Phase 3	[7]
DPK-060	DM059CZ	Atopic dermatitis	EA80	Phase 2	[8]
Brilacidin	DMXI9BP	Acute bacterial skin infection	1C41	Phase 2	[9]
LTX-109	DMXEQ0R	Bacterial infection	1A00-1C4Z	Phase 2	[10]
Friulimicin	DMUI8F3	Bacterial infection	1A00-1C4Z	Phase 1	[11]
IDR-1018	DM1RNT7	Bacterial infection	1A00-1C4Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Cell membrane (Bact CM)	TTXT4D5	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029693)
• [2] Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist. 2012 Apr;18(2):132-6.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
• [6] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [7] In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
• [8] The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29.
• [9] Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
• [10] A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
• [11] Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
• [12] Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.